- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04007562
Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency (LIPIN-1-METAB)
Lipin-1 deficiencies are responsible for severe rhabdomyolysis and muscle pain in childhood. A specific treatment does not exist. Our research team (Pr de Lonlay, Pr Van-Endert, Marine Madrange and Perrine Renard) identified the mechanism of this disease and propose a treatment to decrease rhabdomyolysis outcome and muscle pain. Further to a CPP approval in 2015, several patients have been treated by Hydroxychloroquine Sulfate off label use on a compassionate basis.
The objective of this retrospective study is to describe the safety and efficacy of Hydroxychloroquine Sulfate given on a compassionate basis to patients suffering from Lipin-1 deficiency within a period between 6 and 36 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Lipin-1 deficiency is an inherited autosomal recessive disease caused by two mutations in the LPIN1 gene. Homozygous or compound heterozygous Lipin-1 deficiency causes recurrent acute episodes of rhabdomyolysis and myoglobinuria in children, associated with permanent muscle pain and weakness. The onset of the disease is usually early (before the age of 6 years old) and the disease is severe. The number of acute episodes' ranges from 1 to 10 per patient, mostly during the first 6 years of life (period where illness episodes are most frequent). Some patients die of myoglobinuric bouts, from cardiac arrhythmia, possibly due to hyperkalemia, with a heart probably more sensitive to hyperkaliemia. Mortality rate is around 10%, and is significantly higher when rhabdomyolysis is complicated by renal failure or by cardiac arrest with arrhythmia due to hyperkalemia. A specific treatment does not exist. Altogether these observations indicate that there is a crucial need to identify a treatment.
Our research team (Pr de Lonlay, Pr Van-Endert, Marine Madrange and Perrine Renard) identified the mechanism of this disease. The consequences on myoblasts of patients are TLR9 sequestration in late endosomes and mitophagy impairment, with consecutively mitochondrial DNA accumulation, TLR9 activation, inflammatory cytokines, calcium release and cell death in the presence of TLR9 ligands and a nutrient-poor environment.
Hydroxychloroquine Sulfate, thanks to an anti-TLR9 activity restores control cell phenotypes. In vivo and in vitro results are spectacular. This treatment seems to be able to both decrease the signaling cascade resulting from the activation of TLR9 and to correct the phenotype of patients suffering from the Lipin-1 deficiency.
Further to a CPP approval, several patients have been treated by Hydroxychloroquine Sulfate off label use on a compassionate basis. The objective of this retrospective study is to describe the safety and efficacy of Hydroxychloroquine Sulfate given on a compassionate basis to patients suffering from Lipin-1 deficiency within a period between 6 and 36 months.
Study Type
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker-Enfants Malades
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 3 months
- Minors with Lipin-1 deficiency which were diagnosed with familiar context analysis followed by genetic diagnosis (two causal mutations on the LPIN1 gene) and treated by Hydroxychloroquine Sulfate off label use on a compassionate basis in the Metabolic Diseases Center of Necker Hospital
- Patients treated by Hydroxychloroquine Sulfate for at least 6 months
Exclusion Criteria:
- Opposition of parental authority holders
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lipin-1 deficiency
Patients suffering from Lipin-1 deficiency havebenefited from an off-label use treatment by Hydroxychloroquine Sulfate as part of their care for at least 6 months.
|
The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease: Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency. The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Creatine kinase dosage in plasma
Time Frame: 36 months
|
36 months
|
|
Inflammatory cytokines in plasma
Time Frame: 36 months
|
Quantitative flow cytometry based mutliplex assays (flow cytometry-based systems (BD™ Cytometric Bead Array)).
|
36 months
|
Quantification of mitochondrial DNA in plasma
Time Frame: 36 months
|
Quantitative PCR to detect mitochondrial DNA, 12s gene.
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of intercurrent event
Time Frame: 36 months
|
Clinical examination.
|
36 months
|
Occurrence of rash
Time Frame: 36 months
|
Clinical examination.
|
36 months
|
Gowers sign appearance
Time Frame: 36 months
|
Clinical examination.
|
36 months
|
Occurrence of shortness of breath
Time Frame: 36 months
|
Clinical examination.
|
36 months
|
Occurrence of muscular fatigability
Time Frame: 36 months
|
Clinical examination.
|
36 months
|
Treatment compliance
Time Frame: 36 months
|
Patient interrogation.
|
36 months
|
Occurrence of adverse effect
Time Frame: 36 months
|
Patient interrogation.
|
36 months
|
Dosing of Hydroxychloroquine Sulfate in plasma
Time Frame: 36 months
|
Compliance.
|
36 months
|
Occurence of retinopathy.
Time Frame: 36 months
|
Fundus eye and electroretinogram.
|
36 months
|
Quotation of the different muscles
Time Frame: 36 months
|
Muscle testing by a physiotherapist.
|
36 months
|
6-min walking test
Time Frame: 36 months
|
36 months
|
|
Test of the number of steps during a 3-min walk
Time Frame: 36 months
|
36 months
|
|
Assessment of pain: VAS
Time Frame: 36 months
|
Visual analogue scale (VAS) : scale from 1 to 10; compare from one examination to another for a patient (which is his own control).
|
36 months
|
Quality-of-life assessment: Pediatric Quality of Life InventoryTM (PedsQL) questionnaire
Time Frame: 36 months
|
Pediatric Quality of Life InventoryTM (PedsQL) questionnaire adapted to age: child questionnaire and parent questionnaire.
Questionnaire of 23 questions scored on 5 points, from 0 (never) to 4 (almost always).
The scores are linearly transformed on a scale between 0 and 100, added together and divided by the number of items completed; high scores are associated with a better quality of life related to health.
|
36 months
|
Echocardiography
Time Frame: 36 months
|
Measurement of the wall of the ventricles, ejection fraction.
|
36 months
|
Absence of cardiac arrhythmia
Time Frame: 36 months
|
Electrocardiography
|
36 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pascale de Lonlay, Professor, Assistance Publique - Hôpitaux de Paris
- Study Director: Caroline Tuchmann-Durand, Pharm. D, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Musculoskeletal Pain
- Myalgia
- Rhabdomyolysis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Hydroxychloroquine
Other Study ID Numbers
- APHP190368
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on LIPIN1 Deficiency
-
Nutrition Institute, SloveniaEuropean Regional Development Fund; Vizera d.o.o.; Frutarom Etol d.o.o.CompletedVitamin B 12 Deficiency | Vitamin d Deficiency | Protein DeficiencySlovenia
-
Washington University School of MedicineUniversity of California, Davis; Universidad San Francisco de Quito; Pan American...CompletedCholine Deficiency | Vitamin B-12 Deficiency | Lipids Deficiency | Amino Acids DeficiencyEcuador
-
Texas A&M UniversityUnknownCognitive Change | Nutritional Anemia | Diet, Healthy | Nutrient Deficiency | Diet; Deficiency | Visual Spatial Processing | Dietary Deficiency | Dietary B12 Deficiency | Dietary Zinc Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Deficiency of Selenium and Vitamin EUnited States
-
SourseCitruslabsActive, not recruitingMood | Energy Supply; Deficiency | B12 Deficiency VitaminUnited States
-
University of California, DavisUniversity of California, San Francisco; University of Rhode Island; Ethiopian... and other collaboratorsNot yet recruitingVitamin B 12 Deficiency | Folate Deficiency | Iodine Deficiency | Anemia Deficiency | Salt Intake | Anemia Macrocytic
-
ProofPilotJoovvUnknownTestosterone Deficiency | Estrogen DeficiencyUnited States
-
Meir Medical CenterCompletedFolic Acid Deficiency | Vitamin B12 DeficiencyIsrael
-
University Medical Centre LjubljanaRecruitingBody Weight | IVF | Nutrient Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Folate Deficiency AnemiaSlovenia
-
Nutrition Institute, SloveniaNational Institute of Public Health, Slovenia; University Medical Centre LjubljanaCompletedThyroid Diseases | Iron-deficiency | Vitamin D Deficiency | Nutritional Status | Vitamin B 12 Deficiency | Folic Acid Deficiency | Diet | Nutrient Deficiency | Micronutrient DeficiencySlovenia
-
Quadram Institute BioscienceNorfolk and Norwich University Hospitals NHS Foundation TrustEnrolling by invitationIron Deficiency (Without Anemia) | B12 Deficiency VitaminUnited Kingdom
Clinical Trials on Hydroxychloroquine Sulfate
-
Ravi Amaravadi, MDTerminatedCOVID-19United States
-
Health Institutes of TurkeyCompleted
-
Government of Punjab, Specialized Healthcare and...Harvard School of Public Health (HSPH); Forman Christian College, Pakistan; Services... and other collaboratorsTerminatedCOVID-19 | Coronavirus Infection | SARS-CoV-2 | Asymptomatic ConditionPakistan
-
SandozCompletedImmunosuppression | Rheumatism
-
Apsen Farmaceutica S.A.Federal University of São PauloWithdrawnCoronavirus Infections | SARS-CoV 2 | Pulmonary Disease | SARS (Severe Acute Respiratory Syndrome)Brazil
-
Patrick HensleyActive, not recruitingProstate Cancer RecurrentUnited States
-
Rutgers, The State University of New JerseyTerminatedCOVID-19 | SARS-CoV-2United States
-
Government of Punjab, Specialized Healthcare and...Services Hospital, Lahore; Mayo Hospital Lahore; Pakistan Kidney and Liver InstituteTerminatedCovid-19 | Sars-CoV2 | Symptomatic ConditionPakistan
-
Hackensack Meridian HealthCompletedCovid19United States
-
Peking University First HospitalCompletedHydroxychloroquine | IgA PatientsChina